Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03824483
Title Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

chronic lymphocytic leukemia

Therapies

Obinutuzumab + Venetoclax + Zanubrutinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.